source
- Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchaseMerck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
- Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemiaMarrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…